Maria Pilar Iranzo Alcolea

Dr. Maria Pilar Iranzo Alcolea

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MPMaría López Paraja
María López Paraja
GFGrisell Starita Fajardo
Grisell Starita Fajardo
IVIgnacio Donate Velasco
Ignacio Donate Velasco
DLDavid Lucena López
David Lucena López
MAMaria Pilar Iranzo Alcolea
Maria Pilar Iranzo Alcolea
LMLuis Manzano
Luis Manzano
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare systemic vasculitis characterized by asthma, eosinophilia, and necrotizing inflammation of small- to medium-sized vessels. Accumulating evidence indicates that EGPA is a polygenic and heterogeneous disorder comprising distinct antineutrophil cytoplasmic antibody (ANCA)–defined endotypes with divergent genetic backgrounds, immune pathways, and clinical phenotypes. Its pathogenesis reflects the convergence of epithelial–alarmin signaling, type 2 inflammation, eosinophil effector mechanisms, and B-cell/autoantibody responses, with myeloperoxidase (MPO)-ANCA serving as a hallmark of the vasculitic subset. Recent advances in genomics, immunology, and multi-omics profiling have uncovered biomarkers and molecular circuits sustaining disease activity and guiding therapeutic stratification. The identification of the interleukin (IL)-5–eosinophil axis, epithelial-derived alarmins, and B-cell/IgG4 networks as central pathogenic nodes has enabled the development of targeted biologic therapies that are redefining treatment paradigms. Benralizumab (anti-IL-5Rα) has recently been approved for EGPA following the phase 3 head-to-head MANDARA trial, which demonstrated non-inferiority to mepolizumab in achieving remission (BVAS = 0 with ≤4 mg/day prednisone equivalent) at weeks 36 and 48. These results, together with the established efficacy of mepolizumab, inform practical selection between IL-5 and IL-5Rα blockade and support glucocorticoid-sparing approaches. A structured literature search (2015–2025) was conducted in PubMed, Scopus, and Web of Science to identify recent advances in epidemiology, genetics, biomarkers, and targeted therapies for EGPA. This updated review integrates molecular insights, clinical endotypes, and therapeutic innovations to outline current evidence and future precision-medicine strategies aimed at improving long-term patient outcomes.

28 August 2023 in Revista Española de Casos Clínicos en Medicina Interna
Verified
Journal Article
Open access
PDF file
MAMaria Pilar Iranzo Alcolea
Maria Pilar Iranzo Alcolea
CACarmen Ariño-Palao
Carmen Ariño-Palao
GFGrisell Starita Fajardo
Grisell Starita Fajardo
AAAndrés Andres
Andrés Andres
CCCecilia Suárez Carantoña
Cecilia Suárez Carantoña
La Kikuchi-Fujimoto o linfadenitis histiocítica necrotizante es una enfermedad rara, habitualmente benigna y autolimitada. Sin embargo, en ocasiones se asocia a diferentes manifestaciones sistémicas que pueden condicionar una mortalidad significativa si no se identifican y tratan. Presentamos el caso de una paciente adulta con fiebre y adenopatías con diagnóstico histopatológico de enfermedad de Kikuchi-Fujimoto asociado a síndrome de activación macrofágica y meningitis aséptica. Se realiza también una breve revisión de la literatura sobre esta patología y sus manifestaciones sistémicas asociadas.